Yartemlea (narsoplimab-wuug) for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
Customize your policy alerts
Sign up for all CareSource policy alerts
Know when CareSource releases new policies or updates existing guidance.
Monitor payer policy activity
CareSource Arkansas PASSE medical prior authorization coverage for Yartemlea in members aged 2 years and older with TA-TMA, including initial authorization, reauthorization, dosing, quantity, exclusion, and treatment-duration requirements.
A new policy was created to establish coverage criteria for Yartemlea (narsoplimab-wuug) for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.